临床试验/IRCT20210519051345N54

IRCT20210519051345N54招募中Unknown

In vivo bioequivalence study of Amlodipine/valsartan (5/160) tablet manufactured by Sanamed Co. compared with innovator product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年5月27日

适应症

试验速览

阶段: Unknown
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 59 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney)
•Age (18-59 years)

排除标准

•History of cardiovascular disease, liver and kidney disease
•Alcohol and drug addiction
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Bioeqivalence study of amlodipine valsartan 10/160 mg tabletBioequivalence study.

IRCT20220209053979N5Alborz Darou24

Study of absorption and elimination rate of Amlodipine 5-mg/Valsartan 160-mg tablet in comparison with Amlodipine/Valsartan brand tablet (Exforege®)..

IRCT20200407046981N29Behestan Pharmaceutical Company24

Comparative in vivo evaluation of 2 Amlodipine 10/Valsartan160 mg Tablet formulations.

IRCT20180620040164N36Karen Pharma and Food Supplement Co.24

ong term study of Valsartan and Amlodipine in patients with essential hypertension (extension from Study CVAA489A1301)Hypertension

JPRN-jRCT2080220359ovartis Pharma K.K.400

Bioequivalence study of Amlodipine 10 mg + Valsartan 160 mg film coated tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actover. Amlodipine 10 mg + Valsartan 160 mg film coated tablet with brand EXFORGE® NOVARTIS Tablet..

IRCT20180620040164N20Actover Pharmaceutical Co.24